Swiss National Bank Has $1.57 Million Stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Swiss National Bank cut its position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 7.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 184,000 shares of the biopharmaceutical company’s stock after selling 13,900 shares during the quarter. Swiss National Bank’s holdings in Ocular Therapeutix were worth $1,571,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. AlphaQuest LLC bought a new stake in shares of Ocular Therapeutix during the fourth quarter worth $53,000. Raymond James Financial Inc. acquired a new position in shares of Ocular Therapeutix in the 4th quarter valued at about $1,722,000. Aigen Investment Management LP bought a new position in shares of Ocular Therapeutix during the 4th quarter worth approximately $159,000. Victory Capital Management Inc. boosted its stake in Ocular Therapeutix by 300.4% during the fourth quarter. Victory Capital Management Inc. now owns 68,871 shares of the biopharmaceutical company’s stock worth $588,000 after acquiring an additional 51,671 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of Ocular Therapeutix by 1.9% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,131,485 shares of the biopharmaceutical company’s stock valued at $9,663,000 after buying an additional 21,025 shares during the period. 59.21% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. HC Wainwright reissued a “buy” rating and issued a $15.00 price objective on shares of Ocular Therapeutix in a research note on Tuesday, March 4th. Royal Bank of Canada assumed coverage on shares of Ocular Therapeutix in a research note on Tuesday, March 18th. They issued an “outperform” rating and a $17.00 price objective for the company. Needham & Company LLC started coverage on shares of Ocular Therapeutix in a report on Tuesday, March 11th. They issued a “buy” rating and a $15.00 price target on the stock. Finally, JMP Securities set a $19.00 price objective on Ocular Therapeutix in a report on Tuesday, March 4th. One research analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $16.38.

Insiders Place Their Bets

In other Ocular Therapeutix news, insider Pravin Dugel sold 21,475 shares of the company’s stock in a transaction on Monday, February 24th. The shares were sold at an average price of $6.87, for a total value of $147,533.25. Following the completion of the transaction, the insider now directly owns 3,520,318 shares in the company, valued at approximately $24,184,584.66. This represents a 0.61 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Donald Notman sold 11,119 shares of the firm’s stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $7.81, for a total value of $86,839.39. Following the completion of the transaction, the insider now owns 193,444 shares of the company’s stock, valued at approximately $1,510,797.64. The trade was a 5.44 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 38,895 shares of company stock valued at $283,772 over the last three months. Insiders own 3.50% of the company’s stock.

Ocular Therapeutix Trading Down 2.2 %

Shares of Ocular Therapeutix stock opened at $7.58 on Friday. The company’s 50-day moving average price is $7.53 and its 200-day moving average price is $8.75. The company has a current ratio of 13.01, a quick ratio of 12.94 and a debt-to-equity ratio of 0.19. The company has a market cap of $1.21 billion, a price-to-earnings ratio of -5.74 and a beta of 1.34. Ocular Therapeutix, Inc. has a 12-month low of $4.06 and a 12-month high of $11.78.

Ocular Therapeutix (NASDAQ:OCUL) last released its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.05). The business had revenue of $17.08 million during the quarter, compared to analysts’ expectations of $16.89 million. Ocular Therapeutix had a negative net margin of 283.74% and a negative return on equity of 45.18%. On average, equities analysts expect that Ocular Therapeutix, Inc. will post -0.98 earnings per share for the current fiscal year.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.